60 Degrees Pharmaceuticals, Inc. · NASDAQ:SXTP
60 Degrees Pharmaceuticals — Investor Presentation (July 2026)
30 slides from 60 Degrees Pharmaceuticals's investor presentation, Jul 20, 2026
Slide 1: Corporate Presentation
July 2026 Developing and commercializing new products that address the unmet medical need associated with vector-borne disease Corporate Presentation ©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved.
Slide 2: Disclaimer and Forward-looking Statements
Disclaimer and Forward-looking Statements ©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. DISCLAIMER. The information contained herein has been prepared to assist prospective investors in making their own evaluation of 60 Degrees Pharmaceuticals, Inc. (the "Company") and doe
Slide 3: Investment Thesis
• FDA approved in 2018 • An 8-aminoquinoline antimalarial active against all stages of Plasmodium species • Weekly dose convenience • Robust US distribution network 60 Degrees Pharma (NASDAQ: SXTP) Investment Thesis Mission Developing and commercializing new products that address the unmet medical n
Slide 4: Leadership Team with Decades of Successful Clinical Development and Launch Experience
©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Leadership Team with Decades of Successful Clinical Development and Launch Experience Geoffrey Dow, Chief Executive, President & Director Geoffrey Dow is the CEO, President, and sole Director of 60 Degrees Pharmaceuticals, Inc.
Slide 5: ARAKODA (tafenoquine)
©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. ARAKODA® (tafenoquine) • US FDA approval August 8, 2018, commercially available 2019 • Indicated for the prophylaxis of malaria in patients aged 18 years and older • Key Product Attributes: − ARAKODA is the only prophylactic th
Slide 6: The Burden of Malaria and Impact on US Travelers
©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. The Burden of Malaria and Impact on US Travelers Global Distribution of Malaria Increasing Cases of Malaria Among Returning US Travelers Malaria is a life-threatening disease caused by mosquito- transmitted parasites of the gen
Slide 7: ARAKODA Has Broad-Spectrum Activity at Several Life-Cycle Stages
©2064 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. ARAKODA® Has Broad-Spectrum Activity at Several Life-Cycle Stages for All Plasmodium Species With Convenient Weekly Dosing Why is ARAKODA different?
Slide 8: 100% Protective Efficacy Against Malaria
Tafenoquine 200 mg ©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Tafenoquine 100% Protective Efficacy Against Malaria Naïve Target Population Load then Once Per Week Dosing1 1. McCarthy JS, et al. Clin Infect Dis. 2019;69(3):480-486. doi:10.1093/cid/ciy939 Load First Weekl
Slide 9: Commercial Strategy
Commercial Strategy Drive Commercial Growth Build awareness and utilization of ARAKODA® in the malaria prevention market Shape, Educate and Own the Babesiosis Market Capture first-mover advantage in an underrecognized infection Grow Commercial Revenue Targeting Q4 2026 for profitability ©2026 60 Deg
Slide 10: ARAKODA Sales Growing With Lean Commercial Investment
ARAKODA® Sales Growing With Lean Commercial Investment *A stock out started April 2025 and ended July 2025. ©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. *
Slide 11: Commercial Plans for Malaria Indication 2026 & Beyond
Commercial Plans for Malaria Indication 2026 & Beyond Driving ARAKODA® Utilization & Addressing Access Barriers Increase Awareness and Differentiate ARAKODA Differentiate ARAKODA from the generic competition with a clear and compelling value story ©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL
Slide 12: Babesiosis
Babesiosis Tick-borne disease caused by protozoan parasites of the genus Babesia Babesia microti Disease in US Chronic Babesiosis • Red blood cell parasite transmitted by the same ticks that transmit Lyme (Ixodes) • Non-specific flu-like symptoms, anemia, life- threatening if untreated • Mortality r
Slide 13: Current Treatments for Acute Babesiosis Have Limited Evidence of Efficacy
Current Treatments for Acute Babesiosis Have "Limited Evidence of Efficacy"1 • None of these recommended regimens is approved by the United States Food and Drug Administration • Cure rate of current treatment in retreatment of relapsing- immunosuppressed patients is < 30%* • None of these recommende
Slide 14: Tafenoquine-Atovaquone-Antibiotic Combinations Cured Immunosuppressed Patients
Tafenoquine-Atovaquone-Antibiotic Combinations Cured 4 of 4 Immunosuppressed Patients with Treatment Refractory B. microti Disease When Administered Concurrently for > 6 Weeks1 1. Krause PJ, et al. Clin Infect Dis. doi:10.1093/cid/ciae238 *SXTP internal analysis of data ©2064 60 Degrees Pharmaceutic
Slide 15: ARAKODA for Babesiosis - Clinical Development Plan
©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. ARAKODA® (tafenoquine) for Babesiosis - Clinical Development Plan Randomized Placebo-Controlled Study (NCT06207370) Hospitalized Babesiosis Patients • Tafenoquine (4 x 200/mg then 200 mg/weekly for 4 weeks) + SOC v Placebo + SO
Slide 16: Tafenoquine in Patients Hospitalized for Acute Babesiosis
Tafenoquine in Patients Hospitalized for Acute Babesiosis [See NCT06207370: Study Details | Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis | ClinicalTrials.gov] A Phase II/III, Double-Blind, Randomized Study to Evaluate Oral Tafenoquine Plus Standard of Ca
Slide 17: Expanded Use of Tafenoquine in High-Risk Patients with Relapsing Babesiosis
Expanded Use of Tafenoquine in High-Risk Patients with Relapsing Babesiosis [See NCT06478641: Study Details | Expanded Use in Persistent (B. Microti) Babesiosis | ClinicalTrials.gov] Expanded Access Protocol: Use of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients With Persisten
Slide 18: Phase II Open Label Study of Tafenoquine - Chronic Babesiosis
©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Phase II Open Label Study of Tafenoquine - Chronic Babesiosis 28 A Phase II Open Label Study of Tafenoquine in Chronic Babesiosis Patients Patients: Diagnosis of chronic babesiosis and severe disabling fatigue with substantial
Slide 19: Possible Readouts From Babesiosis Trials and Regulatory Strategy
Possible Readouts From Babesiosis Trials (Best Case) and Regulatory Strategy ©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. • Relapsing Immunosuppressed Patients Treated with Tafenoquine-Atovaquone Triple/Quadruple Combination regimens (NCT 06478641):* −NOW: 3 of 3 cases cu
Slide 20: Regulatory Precedent for sNDA Approval Without Randomized Clinical Trial Data
Regulatory Precedent for sNDA Approval Without Randomized Clinical Trial Data: Approval of Leucovorin to Treat Folate Deficiency in Rare FOLR1 Variants ©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. • Original NDA Approval: 1952 (leucovorin calcium) −High dose methotrexate
Slide 21: Portfolio
©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Executing 3 trials. Targeting completion in 2026 Portfolio July 2026 IND ENABLING PHASE 1 PHASE IIA Phase IIB/III REGULATORY REVIEW = Completed PHASES AND DEVELOPMENT STAGES COMMERCIALLY AVAILABLE ARAKODA (US) Tafenoquine (ARA
Slide 22: Maximum TAM for ARAKODA for Malaria and Babesiosis
MAXIMUM TAM for ARAKODA® for Malaria and Babesiosis ©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. * Maximum possible prescriptions for three weeks of travel (0.75 x 16 ct Arakoda box). Excludes military and US govt sales. Assumes price is not lowered (current WAC is $258 p
Slide 23: Intellectual Property & Licensing
Intellectual Property & Licensing ©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Territory Partner Europe Scandinavian Biopharma Australia, NZ, Pacific Islands Biocelect Revenue Generating License & Distribution Agreements SXTP has freedom to operate: • US Arakoda Patents (
Slide 24: Robust Supply Chain With Flexibility for Growth
Robust Supply Chain With Flexibility for Growth API & Tablets Piramal, India Packaging PCI, Philadelphia, PA, US Distributors ICS, Brooks, KY, US 3PL Title Model ASB, Two Other US Prime Vendors PBMs Various ©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved.
Slide 25: Financial Overview (as of Mar 31, 2026)
Financial Overview (as of Mar 31, 2026)
Slide 26: Recent Financing & Use of Proceeds
Recent Financing & Use of Proceeds ©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. • Common Shares Outstanding: • 2.66 million • Closed @ $1.78 on 6/29/26 • Recent Financing: • Public offering: • $5 million @ $7.60 (7/16/25) • Inactive ATM: • Approx $4M raised between 10/1/2
Slide 27: Achieving Key Milestones Will Derisk Business Plan Through 2027
Achieving Key Milestones Will Derisk Business Plan Through 2027 Q1/2 2026 Q1/2 2026 Q3 2026 Q3 2026 Q4 2026 Q4 2026 New Product Development Partnerships/Licenses B-FREE study to continue Minimum Enrolment for Interim Analysis in Hospital Study Hospital Study Interim Analyses Disclose Final Regulator
Slide 28: Investment Thesis
60 Degrees Pharma (NASDAQ: SXTP) Investment Thesis • Proven Expertise: Commercially available differentiated malaria prevention product addressing $50-70M market in US alone • Strong & Growing IP Portfolio: 3 Orange Book listed patents expiring December 2035 • Pipeline Advancing Treatment in Tick-Bo
Slide 29: Officers & Directors
Officers & Directors Geoffrey Dow, MBA, PHD, CEO & Chairman • Affiliations: WRAIR, USAMMDA • Founded & led 60P from 2010-2023 • Industry Project Leader on Arakoda NDA ©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Tyrone Miller, CFO • CPA • CFO since 2014 • Over 20 years in
Slide 30: Contact
Developing and commercializing new products that address the unmet medical need associated with vector-borne disease 1025 Connecticut Avenue NW Suite 1000 Washington, DC 20036 60degreespharma.com Investor Relations Contact Patrick Gaynes patrickgaynes@60degreespharma.com 310-989-5666 ©2026 60 Degree
60 Degrees Pharmaceuticals — Investor Presentation (July 2026) on 6ix